Pharmaceuticals

A new partnership aims to move AI from costly experiments to real-world value in biopharma, combining specialized agents with strategic implementation.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

Amazon Pharmacy now offers the new Wegovy pill with transparent cash-pay options, shaking up the high-demand weight management drug market.

With a new board appointment and $19M in funding, Enhanced Genomics is leveraging its 3D genomics platform to build its own pipeline of precision therapies.

Automated Industrial Robotics Inc. acquires Ireland's KAON Automation, a strategic move to dominate the high-stakes medical and life sciences market.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

Prescient's acquisition of Uptake creates an integrated giant in healthcare consulting. What does this mean for the industry, clients, and patient outcomes?

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

A new collaboration between the Global Alzheimer's Platform and Alamar Biosciences aims to revolutionize diagnosis with ultra-sensitive blood tests for all.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.